HGVSc	SYMBOL	Consequence	clinvar_clnsig	clinvar_golden_stars	clinvar_rs	clinvar_trait	ClinVar	ClinVar_ALLELEID	ClinVar_CLNDN	ClinVar_CLNDNINCL	ClinVar_CLNDISDB	ClinVar_CLNDISDBINCL	ClinVar_CLNHGVS	ClinVar_CLNREVSTAT	ClinVar_CLNSIG	ClinVar_CLNSIGCONF	ClinVar_CLNSIGINCL	ClinVar_CLNVC	ClinVar_CLNVCSO	ClinVar_CLNVI	ClinVar_DBVARID	ClinVar_GENEINFO	ClinVar_MC	ClinVar_ORIGIN	ClinVar_RS	ClinVar_SSR	ClinVar_CLNSUBA	ClinVar_CLNSIGA	ClinVar_CLNDATEA	ClinVar_CLNDATESUBA	ClinVar_CLNREVSTATA	ClinVar_CLNORA	ClinVar_CLNSCVA	ClinVar_CLNDNA	ClinVar_CLNCOMA	TCGA_eu_cases
NM_002528.6:c.268C>T	NTHL1	stop_gained	5	0	rs150766139	Familial adenomatous polyposis 3	192319	190112	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C4225157,OMIM:616415,Orphanet:ORPHA454840|MedGen:CN517202	-	NC_000016.9:g.2096239G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:602656.0001	-	NTHL1:4913	SO:0001627|intron_variant	1	150766139	-	OMIM|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Invitae|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|Ambry_Genetics	Pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2015-06-01|2017-01-13|2019-01-04|2019-01-08|2018-01-26|2018-10-17	2016-08-11|2018-09-19|2019-01-29|2019-03-28|2018-04-23|2020-02-26	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline|germline	SCV000223893|SCV000705556|SCV000779405|SCV000957470|SCV000992218|SCV001177246	Familial_adenomatous_polyposis_3|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	||This_pathogenic_variant_is_denoted_NTHL1_c.268C>T_at_the_cDNA_level_and_p.Gln90Ter_(Q90X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glycine_to_a_premature_stop_codon_(CAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_observed_in_several_individuals_with_colorectal_cancer_and/or_adenomas_(Dallosso_2008,_Rivera_2015,_Timofeeva_2015,_Weren_2015)._Weren_et_al._(2015)_identified_NTHL1_Gln90Ter_in_the_homozygous_state_in_7_individuals_from_three_families_with_a_history_of_multiple_colorectal_adenomas_and/or_colorectal_cancer._Additionally,_Rivera_et_al._(2015)_identified_NTHL1_Gln90Ter_in_the_compound_heterozygous_state_with_a_canonical_splice_variant,_confirmed_to_be_in_trans_through_familial_testing,_in_an_individual_with_colon_cancer,_multiple_colorectal_adenomas,_and_other_neoplasms._Lastly,_other_studies_identified_NTHL1_Gln90Ter_in_the_homozygous_or_compound_heterozygous_state_in_several_unrelated_individuals_with_colorectal_adenomas_and_colorectal_cancer_(Chubb_2016,_Belhadj_2017,_Broderick_2017)._Based_on_currently_available_information,_we_consider_NTHL1_Gln90Ter_to_be_pathogenic._Of_note,_NTHL1-Associated_Polyposis_(NAP)_is_a_recessive_condition_associated_with_two_pathogenic_variants_on_opposite_chromosomes_in_NTHL1._Although_this_variant_is_considered_pathogenic,_a_second_pathogenic_variant,_as_would_be_required_for_expression_of_the_recessive_condition_NAP,_was_not_detected_in_this_individual._We_cannot_exclude_the_possibility_that_this_patient_harbors_a_second_disease-causing_NTHL1_pathogenic_variant_that_is_undetectable_by_this_test._NTHL1_has_only_recently_been_described_in_association_with_cancer_predisposition_and_the_risks_are_not_well_understood._Based_on_available_data,_the_presence_of_two_pathogenic_variants_in_NTHL1_is_indicative_of_NTHL1-Associated_Polyposis_(NAP),_an_autosomal_recessive_condition_that_may_confer_an_increased_risk_for_colorectal_cancer_and_polyps._Although_the_development_of_colorectal_cancer_and_attenuated_polyposis_appears_to_be_the_predominant_feature_of_NAP,_multiple_case_reports_have_described_individuals_with_NAP_to_have_developed_multiple_extracolonic_neoplasms,_including_breast,_endometrial,_bladder,_and_skin_cancers_as_well_as_several_benign_findings_(Rivera_2015,_Weren_2015,_Belhadj_2017)._The_National_Comprehensive_Cancer_Network_has_management_guidelines_for_individuals_with_two_pathogenic_variants_in_NTHL1_(NCCN).|This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln90*)_in_the_NTHL1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs150766139,_ExAC_0.4%)._This_variant_has_been_observed_as_homozygous,_and_on_the_opposite_chromosome_(in_trans)_from_a_likely_pathogenic_variant,_in_many_individuals_affected_with_multiple_adenomatous_polyps_and_often_colorectal_cancer_(PMID:Â¬â€ 25938944,_27720914,Â¬â€ 26559593)._These_findings_are_consistent_with_autosomal_recessive_inheritance,_and_suggest_that_this_variant_contributes_to_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_192319)._Experimental_studies_have_shown_that_deletion_of_the_N-terminal_92_amino_acids_of_the_NTHL1_protein_results_in_complete_loss_of_its_activity_(PMID:_12144783)._Loss-of-function_variants_in_NTHL1_are_known_to_be_pathogenic_(PMID:_25938944,_26559593)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)	TCGA_UCEC_041;TCGA_UCEC_045
NM_058216.2:c.397C>T	RAD51C	stop_gained	5&5	1&1	rs387907159	Fanconi anemia, complementation group O&Hereditary cancer-predisposing syndrome	31556	40236	Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56772543C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Counsyl:71036|OMIM_Allelic_Variant:602774.0005	-	RAD51C:5889	SO:0001619|non-coding_transcript_variant	1	387907159	-	OMIM|Counsyl|Invitae|Counsyl|Ambry_Genetics|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America	risk_factor|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2012-04-26|2016-06-08|2018-11-02|2016-06-08|2019-01-22|2018-02-20|2019-06-03	2019-08-21|2016-11-23|2019-03-28|2016-11-23|2020-02-26|2019-01-29|2019-09-24	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|unknown|germline|germline|germline	SCV000045555|SCV000489818|SCV000260887|SCV000489817|SCV000274438|SCV000567793|SCV000699808	Breast-ovarian_cancer,_familial_3|Breast-ovarian_cancer,_familial_3|Fanconi_anemia,_complementation_group_O|Fanconi_anemia,_complementation_group_O|Hereditary_cancer-predisposing_syndrome|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome	||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Gln133*)_in_the_RAD51C_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs387907159,_ExAC_0.002%)._This_variant_has_been_reported_in_families_with_breast_and/or_ovarian_cancer_(PMID:_21990120,_22538716)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_31556)._Loss-of-function_variants_in_RAD51C_are_known_to_be_pathogenic_(PMID:_20400964,_21990120,_24800917)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_pathogenic_variant_is_denoted_RAD51C_c.397C>T_at_the_cDNA_level_and_p.Gln133Ter_(Q133X)_at_the_protein_level._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamine_to_a_premature_stop_codon_(CAA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant_has_been_reported_in_individuals_with_breast_and/or_ovarian_cancer_(Loveday_2012,_Thompson_2012)_and_is_considered_pathogenic.|Variant_summary:_RAD51C_c.397C>T_(p.Gln133X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory._The_variant_allele_was_found_at_a_frequency_of_4e-06_in_250888_control_chromosomes_(gnomAD)._c.397C>T_has_been_reported_in_the_literature_in_multiple_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Hu_2018,_Loveday_2012,_Thompson_2011)_including_a_family_in_which_an_unaffected_individual_carried_the_variant_suggesting_reduced_penetrance_(Thompson_2011)._These_data_indicate_that_the_variant_is_very_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Four_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.	TCGA_UCEC_053
NM_000179.2:c.1772del	MSH6	frameshift_variant	-	-	-	-	185350	182081	Hereditary_cancer-predisposing_syndrome	-	SNOMED_CT:699346009	-	NC_000002.11:g.48026894del	_single_submitter	Pathogenic	-	-	Deletion	SO:0000159	-	-	MSH6:2956	SO:0001589|frameshift_variant	1	786202108	-	Ambry_Genetics	Pathogenic	2018-04-23	2020-02-26	_single_submitter	germline	SCV000215432	Hereditary_cancer-predisposing_syndrome	_nonsense)	TCGA_UCEC_068
NM_000179.2:c.843_844insAC	MSH6	frameshift_variant	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TCGA_UCEC_132
NM_014967.4:c.1811+1G>A	FAN1	splice_donor_variant	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TCGA_UCEC_147
NM_007294.3:c.3748G>T	BRCA1	stop_gained	5&5&5&5	3&1&1&1	rs28897686	Breast-ovarian cancer, familial 1&Hereditary breast and ovarian cancer syndrome&not provided&Hereditary cancer-predisposing syndrome	17672	32711	_familial_1|not_specified|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374|MedGen:CN517202	-	NC_000017.10:g.41243800C>A	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	Queen's_University:722481|OMIM_Allelic_Variant:113705.0013	-	BRCA1:672	SO:0001587|nonsense,SO:0001619|non-coding_transcript_variant,SO:0001627|intron_variant	1	28897686	-	OMIM|Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA1)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Evidence-based_Network_for_the_Interpretation_of_Germline_Mutant_Alleles_(ENIGMA)|Consortium_of_Investigators_of_Modifiers_of_BRCA1/2_(CIMBA),_c/o_University_of_Cambridge|Counsyl|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Invitae|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Department_of_Pathology_and_Molecular_Medicine,Queen's_University|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Ambry_Genetics|Color|Baylor_Genetics|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	1994-12-01|2012-04-05|2002-05-29|2015-11-20|2016-09-08|2015-10-02|2015-06-17|0000-00-00|2014-10-08|2015-09-21|2018-12-28|2014-01-31|2017-04-20|2012-11-19|2016-05-23|2018-12-31|2019-07-06|2019-02-11|2016-12-19|2017-02-23|2017-01-11	2018-03-12|2013-12-30|2014-03-28|2016-03-03|2016-09-13|2016-10-28|2017-06-22|2018-04-04|2018-04-17|2018-04-09|2019-03-28|2017-08-04|2017-08-04|2017-04-19|2018-01-25|2019-01-29|2020-03-06|2020-02-26|2017-10-26|2017-02-23|2017-06-30	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000039529|SCV000109357|SCV000144858|SCV000266030|SCV000300004|SCV000325737|SCV000677650|SCV000733619|SCV000743401|SCV000744626|SCV000076324|SCV000587340|SCV000588048|SCV000591470|SCV000699068|SCV000108671|SCV000296296|SCV000186866|SCV000683129|SCV000540952|SCV000602708	Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Breast-ovarian_cancer,_familial_1|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_breast_and_ovarian_cancer_syndrome|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|not_specified	||||Variant_allele_predicted_to_encode_a_truncated_non-functional_protein.||||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Glu1250*)_in_the_BRCA1_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs28897686,_ExAC_0.003%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_ovarian_cancer_(PMID:_7894491,_12497638,_24504028,_24728189)._This_variant_is_also_known_as_3867G>T_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_17672)._Loss-of-function_variants_in_BRCA1_are_known_to_be_pathogenic_(PMID:_20104584)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||||Variant_summary:_The_BRCA1_c.3748G>T_(p.Glu1250X)_variant_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncated_or_absent_BRCA1_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._Truncations_downstream_of_this_position_have_been_classified_as_pathogenic_by_our_laboratory_(e.g.c.3904G>T/p.Glu1302X)._One_in_silico_tool_predicts_a_damaging_outcome_for_this_variant._This_variant_was_found_in_2/121388_control_chromosomes_at_a_frequency_of_0.0000165,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_BRCA1_variant_(0.0010005)._This_variant_has_been_reported_in_multiple_affected_individuals_and_functional_study_showed_variant_with_~10%_of_relative_HDR_activity_in_comparison_to_WT_BRCA1_(Lu_2015)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|This_pathogenic_variant_is_denoted_BRCA1_c.3748G>T_at_the_cDNA_level_and_p.Glu1250Ter_(E1250X)_at_the_protein_level._Using_alternate_nomenclature,_this_variant_would_be_defined_as_BRCA1_3867G>T._The_substitution_creates_a_nonsense_variant,_which_changes_a_Glutamic_Acid_to_a_premature_stop_codon_(GAG>TAG),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._BRCA1_Glu1250Ter_has_been_reported_in_association_with_breast_and_ovarian_cancer_(Castilla_1994,_Ahmad_2012,_Cunningham_2014,_Weren_2016)_and_is_considered_pathogenic.|The_variant_creates_a_premature_nonsense_codon,_and_is_therefore_predicted_to_result_in_the_loss_of_a_functional_protein._Found_in_at_least_one_symptomatic_patient,_and_found_in_general_population_data_that_is_consistent_with_pathogenicity.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|||	TCGA_UCEC_310
NM_000251.2:c.1511-2A>G	MSH2	splice_acceptor_variant	-	-	-	-	90688	96163	Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:CN517202	-	NC_000002.11:g.47693795A>G	reviewed_by_expert_panel	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1511-2A>G	-	MSH2:4436	SO:0001574|splice_acceptor_variant	1	267607962	-	Mayo_Clinic	Pathogenic|Pathogenic|Pathogenic	2013-09-05|2018-08-06|0000-00-00	2013-12-18|2020-02-26|2017-10-31	_single_submitter|no_assertion_criteria_provided	germline|germline|unknown	SCV000107201|SCV000580440|SCV000691905	Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	Variant_causes_splicing_aberration_causing_frameshift:_full_inactivation_of_variant_allele|Functionally-validated_splicing_mutation:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|	TCGA_UCEC_325
NM_000179.2:c.2565del	MSH6	frameshift_variant	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TCGA_UCEC_382
NM_002485.4:c.698_701del	NBN	frameshift_variant,splice_region_variant	-	-	-	-	127878	133335	_normal_intelligence_and_immunodeficiency|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN517202	-	NC_000008.10:g.90983404_90983407del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	OMIM_Allelic_Variant:602667.0002|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2844349	-	NBN:4683	SO:0001589|frameshift_variant	1	587780100	-	_University_of_Chicago|Invitae|GeneReviews|Integrated_Genetics/Laboratory_Corporation_of_America|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic	2018-04-12|2016-07-26|1998-05-01|2015-03-05|2018-12-18|2017-02-02|2018-08-03|2018-07-23|2018-04-11	2020-02-26|2017-10-26|2016-06-24|2015-09-15|2019-03-28|2017-02-02|2019-04-24|2019-01-29|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000213967|SCV000685816|SCV000027554|SCV000248142|SCV000261243|SCV000494629|SCV000917863|SCV000149713|SCV000889556	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|not_provided|not_provided	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)||||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Lys233Serfs*5)_in_the_NBN_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs587780100,_ExAC_0.01%)._This_variant_has_been_observed_inÂ¬â€ individuals_affected_with_Nijmegen_breakage_syndrome_(NBS),_and_breast/ovarian_cancer_(PMID:_9590180,_15474156,_26315354,_26534844)._This_variant_is_also_known_as_698del4_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127878)._Loss-of-function_variants_in_NBN_are_known_to_be_pathogenic_(PMID:_9590180,_16415040)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.||Variant_summary:_NBN_c.698_701delAACA_(p.Lys233SerfsX5)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_2e-05_in_252006_control_chromosomes_(gnomAD)._The_variant,_c.698_701delAACA,_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_and_Nijmegen_Breakage_Syndrome_(Varon_1998,_Gass_2017,_Ramus_2015,_Li_2015,_Susswein_2016)._These_data_indicate_that_the_variant_may_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Six_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|This_deletion_of_four_nucleotides_in_NBN_is_denoted_c.698_701delAACA_at_the_cDNA_level_and_p.Lys233SerfsX5_(K233SfsX5)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_GCCA[delAACA]Ggta,_where_the_capital_letters_are_exonic_and_lowercase_are_intronic._The_deletion_causes_a_frameshift,_changing_a_Lysine_to_a_Serine_at_codon_233,_and_creates_a_premature_stop_codon_at_position_5_of_the_new_reading_frame._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._This_variant,_previously_published_as_NBN_or_NBS1_698del4,_has_been_reported_in_families_with_Nijmegen_Breakage_Syndrome_as_well_as_in_women_with_breast_and_ovarian_cancer_(Varon_1998,_Meyer_2004,_Ramus_2015,_Li_2016,_Gass_2017),_and_is_considered_pathogenic.|	TCGA_UCEC_410
NM_000179.2:c.1135_1139del	MSH6	frameshift_variant	-	-	-	-	89174	94648	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_5|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1833477,OMIM:614350|MedGen:CN517202	-	NC_000002.11:g.48026252_48026256AGAGA[1]	reviewed_by_expert_panel	Pathogenic	-	-	Microsatellite	SO:0000289	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1135_1139del	-	MSH6:2956	SO:0001587|nonsense	1	267608077	-	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Color|GeneDx|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Genetic_Services_Laboratory,_University_of_Chicago|Invitae	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic	2013-09-05|2015-11-20|2018-12-26|2019-02-23|2015-03-30|2018-01-15|0000-00-00|2016-08-19|2018-12-07	2013-12-18|2016-03-03|2019-04-24|2020-02-26|2017-10-26|2019-01-29|2015-11-19|2017-07-05|2019-03-28	reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000107835|SCV000266088|SCV000917791|SCV000184650|SCV000685168|SCV000211383|SCV000257205|SCV000595850|SCV000750903	Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|Hereditary_nonpolyposis_colorectal_cancer_type_5|Hereditary_nonpolyposis_colon_cancer	Coding_sequence_variation_resulting_in_a_stop_codon||Variant_summary:_MSH6_c.1135_1139delAGAGA_(p.Arg379X)_results_in_a_premature_termination_codon,_predicted_to_cause_a_truncation_of_the_encoded_protein_or_absence_of_the_protein_due_to_nonsense_mediated_decay,_which_are_commonly_known_mechanisms_for_disease._The_variant_allele_was_found_at_a_frequency_of_4.1e-06_in_245726_control_chromosomes_(gnomAD)._c.1135_1139delAGAGA_has_been_reported_in_the_literature_in_individuals_affected_with_Breast_cancer,_Ovarian_cancer,_polyups,_and_cervical_cancer_(Frolova_2017,_Kets_2006,_Shirts_2015,_Susswein_2015)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Six_ClinVar_submissions_from_clinical_diagnostic_laboratories_(evaluation_after_2014)_cite_the_variant_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_pathogenic.|Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense):Other_strong_data_supporting_pathogenic_classification||This_deletion_of_5_nucleotides_is_denoted_MSH6_c.1135_1139delAGAGA_at_the_cDNA_level_and_p.Arg379Ter_(R379X)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_braces,_is_GAGA[AGAGA]TGAG._The_deletion_creates_a_nonsense_variant,_which_changes_an_Arginine_to_a_premature_stop_codon._This_variant_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._MSH6_1135_1139delAGAGA_has_been_observed_in_at_least_two_individuals_with_a_personal_history_of_endometrial_cancer_and_a_family_history_of_Lynch_syndrome-related_cancers_(Kets_2006,_Frolova_2015)._This_variant_is_considered_pathogenic.|||This_sequence_change_creates_a_premature_translational_stop_signal_(p.Arg379*)_in_the_MSH6_gene._It_is_expected_to_result_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs777907133,_ExAC_0.001%)._This_variant_has_beenÂ¬â€ observedÂ¬â€ in_several_individuals_affected_with_colorectal_polyps,_endometrial_cancer,_and_cervical_cancer_(PMID:_26845104,_17117178,_26681312,_25617771),_as_well_as_in_individualsÂ¬â€ undergoing_testing_for_Lynch_syndrome_(PMID:Â¬â€ 28514183)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_89174)._Loss-of-function_variants_in_MSH6_are_known_to_be_pathogenic_(PMID:_18269114,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.	TCGA_UCEC_414
NM_024675.3:c.599del	PALB2	frameshift_variant	-	-	-	-	141880	151594	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000016.9:g.23647271del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic	-	-	Deletion	SO:0000159	-	-	PALB2:79728	SO:0001587|nonsense	1	587782081	-	Ambry_Genetics|GeneDx|Invitae	Pathogenic|Pathogenic|Pathogenic	2019-02-11|2018-07-17|2017-12-12	2020-02-26|2019-01-29|2018-04-02	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000185449|SCV000293387|SCV000550716	Hereditary_cancer-predisposing_syndrome|not_provided|Familial_cancer_of_breast	Alterations_resulting_in_premature_truncation_(e.g.reading_frame_shift,_nonsense)|This_deletion_of_one_nucleotide_in_PALB2_is_denoted_c.599delT_at_the_cDNA_level_and_p.Leu200Ter_(L200X)_at_the_protein_level._The_normal_sequence,_with_the_base_that_is_deleted_in_brackets,_is_CTTT[delT]AAGT._The_deletion_causes_a_nonsense_variant,_which_changes_a_Leucine_to_a_premature_stop_codon_(TTA>TAA),_and_is_predicted_to_cause_loss_of_normal_protein_function_through_either_protein_truncation_or_nonsense-mediated_mRNA_decay._PALB2_c.599delT_has_been_reported_in_individuals_with_breast_and/or_ovarian_cancer_(Tung_2016,_Kotsopoulos_2017)._We_consider_this_variant_to_be_pathogenic.|This_sequence_change_deletes_1_nucleotide_from_exon_4_of_the_PALB2_mRNA_(c.599delT),_causing_a_frameshift_at_codon_200._This_creates_a_premature_translational_stop_signal_(p.Leu200*)_and_is_expected_to_result_in_an_absent_or_disrupted_protein_product._Loss-of-function_variants_in_PALB2_are_known_to_be_pathogenic._This_particular_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_cancer_and_ovarian_cancer_(PMID:_26976419,_27631815)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.	TCGA_UCEC_430
NM_000251.2:c.1276+2T>C	MSH2	splice_donor_variant	-	-	-	-	218032	214582	Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome_I|not_provided	-	MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2936783,OMIM:120435|MedGen:CN517202	-	NC_000002.11:g.47657082T>C	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	-	-	MSH2:4436	SO:0001575|splice_donor_variant	1	267607953	-	Mayo_Clinic|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Invitae|Ambry_Genetics|Counsyl	Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic	0000-00-00|2018-10-23|2016-12-23|2017-08-08|2018-10-29|2016-12-14	2015-11-19|2019-01-29|2017-08-01|2018-04-02|2020-02-26|2017-06-22	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline|germline|unknown	SCV000257131|SCV000292623|SCV000601428|SCV000548099|SCV000580619|SCV000677828	not_provided|not_provided|not_provided|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Lynch_syndrome_I	|This_pathogenic_variant_is_denoted_MSH2_c.1276+2T>C_or_IVS7+2T>C_and_consists_of_a_T>C_nucleotide_substitution_at_the_+2_position_of_intron_7_of_the_MSH2_gene._The_variant_destroys_a_canonical_splice_donor_site_and_is_predicted_to_cause_abnormal_gene_splicing,_leading_to_either_an_abnormal_message_that_is_subject_to_nonsense-mediated_mRNA_decay_or_to_an_abnormal_protein_product._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature._Based_on_the_current_evidence,_we_consider_MSH2_c.1276+2T>C_to_be_pathogenic.||This_sequence_change_affects_a_donor_splice_site_in_intron_7_of_the_MSH2_gene._It_is_expected_to_disrupt_RNA_splicing_and_likely_results_in_an_absent_or_disrupted_protein_product._This_variant_is_present_in_population_databases_(rs267607953,_ExAC_0.002%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_MSH2-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_218032)._A_different_variant_affecting_this_nucleotide_(c.1276+2T>A)_has_been_determined_to_be_pathogenic_(PMID:_16395668,_21642682)._This_suggests_that_this_nucleotide_is_important_for_normal_RNA_splicing,_and_that_other_variants_at_this_position_may_also_be_pathogenic._Donor_and_acceptor_splice_site_variants_typically_lead_to_a_loss_of_protein_function_(PMID:_16199547),_and_loss-of-function_variants_in_MSH2_are_known_to_be_pathogenic_(PMID:_15849733,_24362816)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|Alterations_at_the_canonical_donor/acceptor_sites_(+/-_1,_2)_without_other_strong_(b-level)_evidence_supporting_pathogenicity:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation|	TCGA_UCEC_506
NM_006363.4:c.649C>T	SEC23B	stop_gained	5&5	0&1	rs121918226	Congenital dyserythropoietic anemia, type II&not provided	1227	16266	_type_II|not_provided	-	MedGen:C1306589,OMIM:224100,Orphanet:ORPHA98873,SNOMED_CT:68870007|MedGen:CN517202	-	NC_000020.10:g.18505624C>T	_single_submitter	Pathogenic	-	-	single_nucleotide_variant	SO:0001483	HGMD:CM094614|OMIM_Allelic_Variant:610512.0006	-	SEC23B:10483	SO:0001587|nonsense	1	121918226	-	Eurofins_Clinical_Diagnostics	Pathogenic|Pathogenic	2009-09-01|2014-01-30	2018-07-11|2018-09-19	_single_submitter	germline|germline	SCV000021436|SCV000203543	_type_II|not_provided	|	TCGA_UCEC_528
NM_058216.2:c.965+5G>A	RAD51C	splice_region_variant,intron_variant	-	-	-	-	409841	402642	_complementation_group_O	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390	-	NC_000017.10:g.56801466G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(2)	-	single_nucleotide_variant	SO:0001483	-	-	RAD51C:5889	SO:0001627|intron_variant	1	774586107	-	Invitae|Ambry_Genetics|Color	Uncertain_significance|Likely_pathogenic|Uncertain_significance	2016-06-04|2018-05-30|2018-08-24	2017-03-14|2020-02-26|2018-11-06	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline	SCV000550196|SCV000663788|SCV000686408	_complementation_group_O|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_variant_affects_a_highly_conserved_nucleotide_within_the_consensus_splice_site_of_intron_7._The_majority_of_introns_(75%)_have_a_G_nucleotide_at_this_position_(PMID:_9536098)._This_variant_is_present_in_population_databases_(rs774586107,_ExAC_0.002%)._This_variant_has_been_reported_in_in_an_individual_affected_with_ovarian_cancer_(PMID:_22725699)._RT-PCR_analysis_of_mRNA_isolated_from_patient_blood_cells_showed_that_this_variant_leads_to_skipping_of_exon_7_(PMID:_22725699)._In_summary,_this_variant_has_been_reported_in_both_the_population_and_in_an_affected_individual,_and_it_is_likely_to_cause_a_splicing_defect._However,_without_additional_functional_and/or_genetic_data,_this_variant_has_been_classified_as_a_Variant_of_Uncertain_Significance.|Functionally-validated_splicing_mutation:Other_strong_data_supporting_pathogenic_classification:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)|	TCGA_UCEC_061
NM_001128425.1:c.1187G>A	MUTYH	missense_variant,splice_region_variant	5&5&5&5&5	2&0&2&2&0	rs36053993	MYH-associated polyposis&Endometrial carcinoma&not provided&Hereditary cancer-predisposing syndrome&Carcinoma of colon	5294	20333	Small_intestine_carcinoid|Neoplasm_of_stomach|Pilomatrixoma|Carcinoma_of_colon|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|Colorectal_adenomatous_polyposis,_autosomal_recessive,_with_pilomatricomas|not_specified|endometrial_cancer|not_provided	-	Human_Phenotype_Ontology:HP:0006722,MedGen:C1868072|Human_Phenotype_Ontology:HP:0006753,MeSH:D013274,MedGen:C0038356,OMIM:613659,SNOMED_CT:126824007|Human_Phenotype_Ontology:HP:0030434,MeSH:D018296,MedGen:C0206711,OMIM:132600,Orphanet:ORPHA91414|MedGen:C0009402,OMIM:114500,SNOMED_CT:269533000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:C4016911|MedGen:CN169374|MedGen:CN235594|MedGen:CN517202	-	NC_000001.10:g.45797228C>T	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	Center_for_Human_Genetics,_Inc:MUTYH-A4|Donald_Williams_Parsons_Laboratory,Baylor_College_of_Medicine:851773|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2010|HGMD:CM020287|OMIM_Allelic_Variant:604933.0002	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	36053993	-	OMIM|Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|GeneReviews|Invitae|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Donald_Williams_Parsons_Laboratory,Baylor_College_of_Medicine|Counsyl|Center_for_Human_Genetics,_Inc|Mendelics|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|OMIM|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Ambry_Genetics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Vantari_Genetics|Color|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|True_Health_Diagnostics|GeneKor_MSA|ITMI|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Pathway_Genomics|Division_of_Human_Genetics,Children's_Hospital_of_Philadelphia|Endocrine_oncology_group,Uppsala_University|Genetic_Services_Laboratory,_University_of_Chicago|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|GenomeConnect,_ClinGen	Pathogenic|pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|not_provided|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|not_provided	2011-09-01|2012-07-13|2019-10-08|2019-01-11|2015-03-04|2016-11-09|2015-10-12|2015-07-01|2016-11-01|2018-07-02|2019-12-18|2011-09-01|2018-02-27|2018-10-29|2016-08-15|0000-00-00|2016-03-22|2019-07-31|2015-11-20|2015-12-21|2016-02-16|2018-05-23|2017-12-29|2018-08-01|2013-09-19|2018-08-01|2014-07-24|2015-06-04|2017-03-09|2016-08-26|2017-05-18|2017-08-09|0000-00-00	2019-08-20|0000-00-00|2019-12-13|2019-03-28|2019-03-21|2017-04-19|2016-08-18|2017-06-22|2017-12-20|2018-08-20|2019-12-18|2019-08-20|2018-09-19|2019-01-29|2018-08-31|2017-10-31|2018-01-29|2020-02-26|2016-03-03|2016-03-29|2017-01-26|2018-05-23|2018-03-08|2018-08-08|2014-05-29|2019-08-05|2014-08-08|2017-01-23|2017-06-12|2017-07-05|2017-05-23|2018-01-25|2018-03-13	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided	germline|germline|germline|germline|germline|germline|germline|unknown|germline|unknown|unknown|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|unknown	SCV000025796|SCV000043370|SCV000057867|SCV000166443|SCV000245638|SCV000592711|SCV000599972|SCV000678192|SCV000781800|SCV000837751|SCV000993433|SCV000025797|SCV000111383|SCV000149657|SCV000601628|SCV000691947|SCV000806339|SCV000184573|SCV000266099|SCV000267061|SCV000537630|SCV000679736|SCV000788060|SCV000821744|SCV000085795|SCV000604306|SCV000189964|SCV000536693|SCV000536689|SCV000595873|SCV000611285|SCV000697670|SCV000840099	MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|endometrial_cancer|not_provided|not_provided|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|Carcinoma_of_colon|MYH-associated_polyposis/Neoplasm_of_stomach|Small_intestine_carcinoid|Colorectal_adenomatous_polyposis,_autosomal_recessive,_with_pilomatricomas|MYH-associated_polyposis/Pilomatrixoma/Neoplasm_of_stomach|MUTYH-associated_polyposis|MUTYH-associated_polyposis	|Converted_during_submission_to_Pathogenic.||This_sequence_change_replaces_glycine_with_aspartic_acid_at_codon_396_of_the_MUTYH_protein_(p.Gly396Asp)._The_glycine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_glycine_and_aspartic_acid._This_variant_is_a_known_common_cause_of_MUTYH-associated_polyposis_(PMID:_23035301)._This_variant_has_been_reported_to_co-segregate_with_disease_in_individuals_affected_with_colorectal_cancer,_familial_adenomatous_polyposis_(FAP),_and_attenuated_FAP_(PMID:_11818965,_16557584,_17489848,_19793053).Â¬â€ This_variant_is_also_known_as_c.1145G>A_(p.Gly382Asp)_in_the_literature.Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_5294)._MUTYH-related_conditions_are_inherited_in_an_autosomal_recessive_fashion._However,_there_is_evidence_that_monoallelic_pathogenic_MUTYH_variants_including_this_particular_variant_are_associated_with_increased_risk_of_colon_cancer_(PMID:_16492921,_19394335,_21171015,_24444654,_15931596)._Experimental_studies_have_shown_that_this_missense_change_disrupts_MUTYH_protein_function_(PMID:_15987719,_18534194,_20848659,_23108399)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|The_p.Gly396Asp_variant_in_MUTYH_is_a_well-established_pathogenic_variant_for_MU_TYH-related_attenuated_familial_adenomatous_polyposis_and_is_estimated_to_accoun_t_for_50-82%_of_MUTYH-associated_polyposis_in_European_patients_(Al-Tassan_2002,_Nielsen_2009,_Vogt_2009,_Nascimbeni_2010,_Aretz_2014,_ClinVar:_Variation_ID_529_4)._In_vitro_functional_studies_provide_some_evidence_that_the_p.Gly396Asp_varia_nt_may_impact_protein_function_(Al-Tassan_2002,_Ali_2008,_Goto_2010)._This_vari_ant_has_also_been_identified_in_0.5%_(608/126146)_of_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org/:_dbSNP_r_s36053993):_however,_this_frequency_is_low_enough_to_be_consistent_with_a_recess_ive_carrier_frequency._Computational_prediction_tools_and_conservation_analysis_suggest_that_the_p.Gly396Asp_variant_may_impact_the_protein._In_summary,_this_va_riant_meets_criteria_to_be_classified_as_pathogenic_for_MUTYH-associated_polypos_is_in_an_autosomal_recessive_manner._ACMG/AMP_Criteria_applied:_PM3_VeryStrong,_PP3,_PS3_Supporting.||This_variant_has_been_previously_reported_as_disease-causing._It_would_be_pathogenic_in_a_recessive_state:_heterozygotes_would_be_carriers_for_the_condition._It_was_found_once_in_our_study_heterozygous_in_a_6-year-old_male_with_anaplastic_ganglioglioma.|||||||This_pathogenic_variant_is_denoted_MUTYH_c.1187G>A_at_the_cDNA_level,_p.Gly396Asp_(G396D)_at_the_protein_level,_and_results_in_the_change_of_a_Glycine_to_an_Aspartic_Acid_(GGT>GAT)._MUTYH_Gly396Asp,_also_annotated_as_Gly382Asp_using_a_different_gene_transcript,_is_one_of_two_common_MUTYH_pathogenic_variants_which_together_account_for_up_to_80%_of_pathogenic_MUTYH_variants._It_has_been_observed_in_the_homozygous_and_compound_heterozygous_state_in_multiple_individuals_with_MUTYH-Associated_Polyposis,_including_affected_siblings_(Al-Tassan_2002,_de_Leon_2017,_Yurgelun_2017)._Multiple_in_vitro_functional_studies_demonstrate_this_variant's_pathogenic_effect_(Al-Tassan_2002,_Ali_2008,_Goto_2010)._MUTYH_Gly396Asp_was_observed_at_an_allele_frequency_of_0.48%_(611/126146)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_8-oxo-G_binding_site_within_the_Nudix_domain_(Ruggieri_2013)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._We_consider_this_variant_to_be_pathogenic.||||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Deficient_protein_function_by_in_vitro/ex_vivo_assay:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:Other_strong_data_supporting_pathogenic_classification||||||||The_MUTYH_c.1187G>A:_p.Gly396Asp_variant_(rs36053993:_also_known_as_NM_001048171.1:_c.1145G>A:_p.Gly382Asp)_has_been_well_described_in_the_literature_as_one_of_the_two_common_MUTYH_pathogenic_variants._It_has_been_observed_in_homozygous_or_compound_heterozygous_form_with_other_pathogenic_MUTYH_variants_in_patients_with_adenomatous_polyposis_syndrome_(Al-Tassan_2002,_Nielsen_2009,_Ruggieri_2013),_and_is_enriched_in_patients_with_an_odds_ratio_of_6.47_(Theodoratou_2010)._Functional_characterization_of_the_variant_protein_indicates_a_partial_reduction_in_DNA_binding_and_glycosylase_activity_(Ali_2008,_D'Agostino_2010,_Goto_2010,_Komine_2015,_Kundu_2009,_Molatore_2010,_Ruggieri_2013)._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._REFERENCES_Ali_M_et_al._Characterization_of_mutant_MUTYH_proteins_associated_with_familial_colorectal_cancer._Gastroenterology._2008_135(2):499-507._Al-Tassan_N_et_al._Inherited_variants_of_MYH_associated_with_somatic_G:C-->T:A_mutations_in_colorectal_tumors._Nat_Genet._2002_30(2):227-32._D'Agostino_V_et_al._Functional_analysis_of_MUTYH_mutated_proteins_associated_with_familial_adenomatous_polyposis._DNA_Repair_(Amst)._2010_9(6):700-7._Goto_M_et_al._Adenine_DNA_glycosylase_activity_of_14_human_MutY_homolog_(MUTYH)_variant_proteins_found_in_patients_with_colorectal_polyposis_and_cancer._Hum_Mutat._2010_31(11):E1861-74._Komine_K_et_al._Functional_Complementation_Assay_for_47_MUTYH_Variants_in_a_MutY-Disrupted_Escherichia_coli_Strain._Hum_Mutat._2015_36(7):704-11._Kundu_S_et_al._Adenine_removal_activity_and_bacterial_complementation_with_the_human_MutY_homologue_(MUTYH)_and_Y165C,_G382D,_P391L_and_Q324R_variants_associated_with_colorectal_cancer._DNA_Repair_(Amst)._2009_8(12):1400-10._Molatore_S_et_al._MUTYH_mutations_associated_with_familial_adenomatous_polyposis:_functional_characterization_by_a_mammalian_cell-based_assay._Hum_Mutat._2010_31(2):159-66._Nielsen_M_et_al._Analysis_of_MUTYH_genotypes_and_colorectal_phenotypes_in_patients_With_MUTYH-associated_polyposis._Gastroenterology._2009_136(2):471-6._Ruggieri_V_et_al._Loss_of_MUTYH_function_in_human_cells_leads_to_accumulation_of_oxidative_damage_and_genetic_instability._Oncogene._2013_32(38):4500-8._Theodoratou_E_et_al._A_large-scale_meta-analysis_to_refine_colorectal_cancer_risk_estimates_associated_with_MUTYH_variants._Br_J_Cancer._2010_Dec_7:103(12):1875-84.||||||Variant_summary:_The_MUTYH_c.1187G>A_(p.Gly396Asp)_variant_involves_the_alteration_of_a_conserved_nucleotide._3/4_in_silico_tools_predict_a_damaging_outcome_for_this_variant._Functional_studies_support_a_damaging_outcome,_and_at_least_2_independent_labs_have_down_reduced_DNA_glycosylase_activity_and_a_reduced_ability_to_suppress_the_mutation_frequency_in_a_complementation_assay._This_variant_was_found_in_339/120440_control_chromosomes_(2_homozygotes)_at_a_frequency_of_0.0028147,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MUTYH_variant_(0.0045644)._The_variant_has_been_reported_in_numerous_patients_in_the_literature,_and_is_known_as_a_common_pathogenic_variant._In_addition,_many_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|GenomeConnect_assertions_are_reported_exactly_as_they_appear_on_the_patient-provided_report_from_the_testing_laboratory._GenomeConnect_staff_make_no_attempt_to_reinterpret_the_clinical_significance_of_the_variant.	TCGA_UCEC_062;TCGA_UCEC_185;TCGA_UCEC_259;TCGA_UCEC_288;TCGA_UCEC_300
NM_007194.3:c.1427C>T	CHEK2	missense_variant	4&4	1&1	rs142763740	Hereditary cancer-predisposing syndrome&not provided	128060	133517	_susceptibility_to|not_specified|CHEK2-Related_Cancer_Susceptibility|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1527249|MedGen:C1858433|MedGen:CN169374|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29090054G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(8)	-	single_nucleotide_variant	SO:0001483	Illumina:655839	-	CHEK2:11200	SO:0001583|missense_variant	17	142763740	-	Ambry_Genetics|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|GeneID_Lab_-_Advanced_Molecular_Diagnostics|Color|GeneKor_MSA|Invitae|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Counsyl|Mendelics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|PreventionGenetics,PreventionGenetics|Illumina_Clinical_Services_Laboratory,Illumina|Illumina_Clinical_Services_Laboratory,Illumina|Genetic_Services_Laboratory,_University_of_Chicago|Illumina_Clinical_Services_Laboratory,Illumina	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic	2019-08-16|2017-02-14|2017-09-07|2018-10-03|2018-08-01|2018-12-30|2018-04-16|2017-10-06|2018-07-02|2015-11-20|2019-01-07|2018-12-10|2016-10-14|2016-09-30|2016-06-14|2016-06-14|2016-11-21|2017-04-27	2020-02-26|2017-02-16|2017-09-11|2018-11-06|2018-08-08|2019-03-28|2018-05-24|2018-06-20|2018-08-20|2016-03-03|2019-01-29|2020-03-06|2018-01-25|2018-01-29|2016-10-18|2016-10-18|2017-07-05|2019-02-01	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000186804|SCV000576430|SCV000680448|SCV000689655|SCV000821724|SCV000254925|SCV000778585|SCV000785095|SCV000839455|SCV000266166|SCV000149910|SCV000601155|SCV000698777|SCV000806869|SCV000437713|SCV000437714|SCV000594113|SCV000914986	_susceptibility_to|not_provided|not_provided|not_provided|not_provided|Colorectal_cancer|Neoplasm_of_the_breast|not_specified|CHEK2-Related_Cancer_Susceptibility	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)|||||This_sequence_change_replaces_threonine_with_methionine_at_codon_476_of_the_CHEK2_protein_(p.Thr476Met)._The_threonine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_threonine_and_methionine._This_variant_is_present_in_population_databases_(rs142763740,_ExAC_0.07%)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_21244692),_endometrial_cancer_(PMID:_27443514),_colorectal_cancer_(PMID:Â¬â€ 28944238),_prostate_cancer_(PMID:Â¬â€ 29368341,Â¬â€ 29520813),_and_in_a_male_with_breast_and_colon_cancer_(PMID:_28008555)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128060)._Experimental_studies_have_shown_that_this_missense_change_disrupts_CHEK2_kinase_activity_in_vitro_and_impairs_DNA_damage_response_in_a_yeast_assay_(PMID:_22114986,_22419737)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||||This_variant_is_denoted_CHEK2_c.1427C>T_at_the_cDNA_level,_p.Thr476Met_(T476M)_at_the_protein_level,_and_results_in_the_change_of_a_Threonine_to_a_Methionine_(ACG>ATG)._This_variant_has_been_reported_in_individuals_with_a_personal_and/or_family_history_of_breast,_pancreatic,_or_prostate_cancer_(Desrichard_2011,_Le_Calvez-Kelm_2011,_Hu_2015,_Leedom_2016,_Pritzlaff_2016,_Shirts_2016,_Frey_2017,_Isaacsson_Velho_2018,_Schubert_2018,_Wu_2018)._This_variant_was_shown_in_an_in_vitro_study_to_abolish_kinase_activity,_and_was_shown_in_an_in_vivo_study_to_impair_CHEK2-mediated_response_to_DNA_damage_(Desrichard_2011,_Roeb_2012)._A_different_nucleotide_change_(CHEK2_c.1427C>A)_resulting_in_the_same_amino_acid_substitution_was_identified_in_a_patient_with_a_clinical_diagnosis_of_Li-Fraumeni_syndrome_(Sadri_2014)._Although_this_variant_was_observed_in_large_population_cohorts,_population_data_in_this_region_of_CHEK2_are_not_considered_reliable_due_to_high_pseudogene_homology_(Lek_2016)._CHEK2_Thr476Met_is_located_in_the_protein_kinase_domain_(Cai_2009,_Roeb_2012)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_the_currently_available_evidence,_we_consider_CHEK2_Thr476Met_to_be_a_likely_pathogenic_variant.|The_best_available_variant_frequency_is_uninformative._Statistically_enriched_in_patients_compared_to_ethnically_matched_controls._Found_in_at_least_one_symptomatic_patient._Predicted_to_have_a_damaging_effect_on_the_protein._Occurs_in_a_single_case_with_an_otherwise_positive_result._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.||||Across_three_studies,_the_c.1427C>T_(p.Thr476Met),_was_reported_in_five_of_1,955_breast_cancer_patients_(Le_Calvez-Kelm_et_al._2011:_Desrichard_et_al._2011:_Angelova_et_al._2012)._The_variant_was_absent_from_a_total_of_1,622_controls,_but_is_reported_at_a_frequency_of_0.00068_in_the_European_(Non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Desrichard_et_al._(2011)_developed_an_in_vitro_kinase_activity_assay_to_assess_the_activity_of_missense_variants_in_CHEK2._In_this_assay_the_p.Thr476Met_variant_demonstrated_no_kinase_activity_and_was_similar_to_a_known_non-functional_kinase_variant_of_CHEK2._In_addition,_Roeb_et_al._(2012)_developed_a_yeast-based_in-vivo_functional_assay_to_assess_the_effect_of_CHEK2_variants_on_the_repair_of_DNA_damage._Cells_with_wild-type_CHEK2_repaired_the_DNA_damage_while_cells_with_a_known_non-functional_variant_of_CHEK2_did_not._The_p.Thr476Met_variant_was_shown_to_have_loss_of_function_by_this_DNA_damage_response_assay._Based_on_the_evidence,_the_p.Thr476Met_variant_is_classified_as_likely_pathogenic_for_breast_cancer.||The_CHEK2_c.1427C>T_(p.Thr476Met)_missense_variant,_also_referred_to_as_c.1556C>T_(p.Thr519Met),_was_reported_in_five_of_1,955_breast_cancer_patients_(Le_Calvez-Kelm_et_al._2011:_Desrichard_et_al._2011:_Angelova_et_al._2012)._The_variant_was_absent_from_a_total_of_1,622_controls,_but_is_reported_at_a_frequency_of_0.00068_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Desrichard_et_al._(2011)_developed_an_in_vitro_kinase_activity_assay_to_assess_the_activity_of_missense_variants_in_CHEK2._In_this_assay_the_p.Thr476Met_variant_demonstrated_no_kinase_activity_and_was_similar_to_a_known_non-functional_kinase_variant_of_CHEK2._In_addition,_Roeb_et_al._(2012)_developed_a_yeast-based_in-vivo_functional_assay_to_assess_the_effect_of_CHEK2_variants_on_the_repair_of_DNA_damage._Cells_with_wild_type_CHEK2_repaired_the_DNA_damage_while_cells_with_a_known_non-functional_variant_of_CHEK2_did_not._The_p.Thr476Met_variant_was_shown_to_have_loss_of_function_by_this_DNA_damage_response_assay._Based_on_the_evidence,_the_p.Thr476Met_variant_is_classified_as_pathogenic_for_CHEK2-related_cancer_susceptibility._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.	TCGA_UCEC_160
NM_007194.3:c.470T>C	CHEK2	missense_variant	5&5&4&4	0&2&1&1	rs17879961	Li-Fraumeni syndrome 2&Hereditary cancer-predisposing syndrome&Breast and colorectal cancer, susceptibility to&not provided	5591	20630	Cancer_of_multiple_types,_susceptibility_to|Prostate_cancer,_susceptibility_to|Gastrointestinal_carcinoma|Adrenocortical_carcinoma|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome_2|Breast_and_colorectal_cancer,_susceptibility_to|Colorectal_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|COLON_CANCER,_SUSCEPTIBILITY_TO|not_specified|not_provided	-	.|.|Human_Phenotype_Ontology:HP:0002672,MedGen:C0151544|Human_Phenotype_Ontology:HP:0006744,MeSH:D018268,MedGen:C0206686,Orphanet:ORPHA1501|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836482,OMIM:609265|MedGen:C1858433|MedGen:C1858438|MedGen:C3469522|MedGen:C4016820|MedGen:CN169374|MedGen:CN517202	-	NC_000022.10:g.29121087A>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_pathogenic(7),Pathogenic(7),Uncertain_significance(3)	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:181664|OMIM_Allelic_Variant:604373.0002|UniProtKB_(protein):O96017#VAR_008555	-	CHEK2:11200	SO:0001583|missense_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	17879961	-	OMIM|OMIM|OMIM|OMIM|Ambry_Genetics|Color|True_Health_Diagnostics|GeneKor_MSA|ITMI|Integrated_Genetics/Laboratory_Corporation_of_America|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Pathway_Genomics|Invitae|Counsyl|Mendelics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Center_of_Medical_Genetics_and_Primary_Health_Care|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Division_of_Genomic_Diagnostics,The_Children's_Hospital_of_Philadelphia|GeneDx|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Genetic_Services_Laboratory,_University_of_Chicago|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana|GenomeConnect,_ClinGen	Pathogenic|risk_factor|risk_factor|risk_factor|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|not_provided|Uncertain_significance|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Uncertain_significance|not_provided	2006-11-01|2006-11-01|2006-11-01|2006-11-01|2018-06-20|2014-12-26|2017-11-16|2018-08-01|2013-09-19|2019-04-15|2019-01-02|2014-07-24|2019-01-09|2016-03-15|2018-07-02|2017-06-02|0000-00-00|2015-11-20|2018-05-03|2019-09-30|2019-04-01|2017-02-17|0000-00-00|2016-09-14|2017-06-13|2017-01-01|0000-00-00	2011-11-22|2011-11-22|2011-11-22|2011-11-22|2020-02-26|2016-07-05|2018-03-08|2018-08-08|2014-05-29|2019-09-24|2019-08-05|2014-08-08|2019-03-28|2017-06-22|2018-08-20|2018-06-14|2019-08-31|2016-03-03|2018-05-04|2020-01-06|2019-07-12|2017-08-01|2017-10-31|2018-01-29|2017-07-05|2017-12-08|2019-01-30	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|unknown|unknown	SCV000026118|SCV000026119|SCV000026120|SCV000026121|SCV000183804|SCV000292120|SCV000788004|SCV000821722|SCV000084709|SCV000698803|SCV001159433|SCV000189923|SCV000253984|SCV000677722|SCV000839491|SCV000839939|SCV000987254|SCV000266064|SCV000296968|SCV000149927|SCV000575329|SCV000601169|SCV000691835|SCV000806880|SCV000594119|SCV000747421|SCV000986797	Li-Fraumeni_syndrome_2|Colorectal_cancer,_susceptibility_to|Cancer_of_multiple_types,_susceptibility_to|Prostate_cancer,_susceptibility_to|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|not_specified|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and_colorectal_cancer,_susceptibility_to|Breast_and_colorectal_cancer,_susceptibility_to|not_provided|not_provided|not_provided|not_provided|not_provided|Breast_cancer,_susceptibility_to|Gastrointestinal_carcinoma/Adrenocortical_carcinoma|Breast_cancer,_susceptibility_to/COLON_CANCER,_SUSCEPTIBILITY_TO	||||Significant_disease_association_in_appropriately_sized_case-control_study(ies):Deficient_protein_function_in_appropriate_functional_assay(s):Other_strong_data_supporting_pathogenic_classification|||||Variant_summary:_CHEK2_c.470T>C_(p.Ile157Thr)_results_in_a_non-conservative_amino_acid_change_located_in_the_Forkhead-associated_(FHA)_domain_(IPR000253)_of_the_encoded_protein_sequence._Four_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_0.0042_in_253524_control_chromosomes_in_the_gnomAD_database,_including_11_homozygotes._The_observed_variant_frequency_is_approximately_13.5_fold_of_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_CHEK2_causing_Hereditary_Breast_and_Ovarian_Cancer_phenotype_(0.00031)._In_addition,_this_variant_has_been_reported_in_47/7325_European_American_women_(including_1_homozygote)_who_are_older_than_age_70_and_cancer_free_(in_the_FLOSSIES_database)._These_data_suggest_that_the_variant_is_benign_polymorphism._However,_c.470T>C_has_been_reported_in_the_literature_in_several_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer._In_families_with_this_variant,_transmissions_of_the_variant_allele_and_transmissions_of_the_reference_allele_to_affected_individuals_was_reported_in_addition_to_unaffected_individuals_who_harbored_the_variant_(Allinen_2001,_Dong_2003,_Roeb_2012,_Bak_2014,_Cragun_2014,_Stradella_2018)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease_but_also_suggests_incomplete_segregation_and_incomplete_penetrance_associated_with_this_variant._Co-occurrences_with_other_pathogenic_variants_have_been_reported_in_CHEK2_as_well_as_in_other_genes_associated_with_cancer_(e.g._BRCA2_c.6468_6469delTC_[p.Gln2157fsX18]:_NBN_c.657_661delACAAA_[p.Lys219fsX16]:_BRCA1_c.3700_3704delGTAAA_[p.Val1234fsX8]:_CHEK2_c.444+1G>A:_CHEK2_1100delC_[p.Thr367fsX15]:_CHEK2_c.433C>T_[p.Arg145Trp]),_providing_supporting_evidence_for_a_benign_role,_though_in_some_of_these_cases_the_observed_phenotype_(earlier_onset),_could_also_suggest_an_additive_effect_(Stradella_2018)._Multiple_association_studies_have_produced_conflicting_results,_but_with_an_overall_consensus_for_the_variant_being_associated_with_a_moderate_increased_risk_for_breast_cancer_based_on_a_large_meta-analysis_by_Liu_2012_that_included_a_total_of_fifteen_case-control_studies_(19,621_cases_and_27,001_controls),_showing_a_significant_association_for_unselected_breast_cancer_(OR_	TCGA_UCEC_285;TCGA_UCEC_471
NM_058216.2:c.1026+5_1026+7del	RAD51C	splice_region_variant,intron_variant	-	-	-	-	128201	133658	Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|Breast-ovarian_cancer,_familial_3|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3150653,OMIM:613390|MedGen:C3150659,OMIM:613399|MedGen:CN517202	-	NC_000017.10:g.56809910_56809912del	criteria_provided,_multiple_submitters,_no_conflicts	Pathogenic/Likely_pathogenic	-	-	Deletion	SO:0000159	-	-	RAD51C:5889	SO:0001627|intron_variant	1	587781410	-	Ambry_Genetics|Color|Invitae|GeneDx|PreventionGenetics,PreventionGenetics|Laboratoire_de_Biologie_et_Génétique_du_Cancer,Centre_François_Baclesse|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Counsyl	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic	2019-10-09|2018-10-17|2018-12-28|2018-11-15|2016-10-17|0000-00-00|2018-05-17|2016-08-06	2020-02-26|2018-11-06|2019-03-28|2019-01-29|2018-01-29|2017-03-06|2018-11-05|2017-06-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown	SCV000184030|SCV000691214|SCV000255311|SCV000150079|SCV000807165|SCV000536678|SCV000886446|SCV000677795	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_O|not_provided|not_provided|Breast-ovarian_cancer,_familial_3|Breast-ovarian_cancer,_familial_3|Breast-ovarian_cancer,_familial_3/Fanconi_anemia,_complementation_group_O	Deficient_protein_function_in_appropriate_functional_assay(s):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_sequence_change_falls_in_intron_8_of_the_RAD51C_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_RAD51C_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_present_in_population_databases_(rs587781410,_ExAC_0.004%)._This_variant_has_been_reported_in_the_literature_in_individuals_affected_with_breast_cancer,_ovarian_cancer,_and_uterine_cancer,_as_well_as_in_an_unaffected_control_individual_(PMID:_22538716,_24139550,_26057125,_27616075,Â¬â€ 29255180)._Segregation_studies_have_not_been_reported_for_this_variant._ClinVar_also_contains_an_entry_for_this_variant_(Variation_ID:_128201)._This_small_deletion_disrupts_the_consensus_donor_splice_site_at_intron_8_of_the_RAD51C_gene._RT-PCR_analysis_using_RNA_extracted_from_the_peripheral_blood_of_carrier_individuals_shows_that_this_variant_may_lead_to_the_skipping_of_exon_8,_resulting_in_a_frameshift_and_the_generation_of_a_premature_stop_codon_in_the_final_exon_of_RAD51C_(PMID:_24139550,_26057125,_28905878)._Although_it_is_not_predicted_to_result_in_nonsense_mediated_decay,_it_does_affect_the_C-terminus_of_the_RAD51C_protein,_which_includes_a_nuclear_localization_signal_that_when_deleted_has_been_shown_to_cause_cellular_mislocalization_(PMID:_12966089)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|This_variant_is_denoted_RAD51C_c.1026+5_1026+7delGTA_or_IVS8+5_IVS8+7delGTA_and_consists_of_a_deletion_of_three_nucleotides_at_the_+5_to_+7_positions_in_intron_8_of_the_RAD51C_gene._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_gtca[delgta]ttat._This_variant_has_been_observed_in_at_least_four_breast/ovarian_cancer_families,_as_well_as_in_one_healthy_control_(Loveday_2012,_Golmard_2013,_Janatova_2015,_Kraus_2017)._In_silico_analyses,_which_include_splice_predictors_and_evolutionary_conservation,_are_inconsistent_in_their_assessment_as_to_whether_or_not_the_variant_is_damaging:_however,_mRNA_studies_showed_this_variant_causes_out-of-frame_skipping_of_exon_8,_resulting_in_a_frameshift_and_truncated_protein_(Golmard_2013,_Davy_2017)._The_disrupted_region_at_the_end_of_the_gene_includes_the_nuclear_localization_signal_(French_2003)._RAD51C_c.1026+5_1026+7delGTA_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._Based_on_currently_available_evidence,_we_consider_RAD51C_c.1026+5_1026+7delGTA_to_be_a_likely_pathogenic_variant.|||The_RAD51C_variant_designated_as_NM_058216.2:c.1026+5_1026+7delGTA_was_previously_classified_as_a_variant_of_uncertain_significance_and_is_now_classified_as_likely_pathogenic._This_variant_is_a_nucleotide_deletion_that_affects_a_consensus_splice_site_in_intron_8_of_the_RAD51C_gene._RNA_studies_of_peripheral_blood_from_individuals_with_the_variant_have_demonstrated_that_the_variant_leads_to_skipping_of_exon_8,_resulting_in_a_frameshift_and_the_generation_of_a_premature_stop_codon_in_the_final_exon_(Golmard_2013,_PMID:241395:_Janatova_2015,_PMID:26057125)._Nonsense-mediated_decay_is_not_expected_to_result_from_this_variant,_but_it_leads_to_a_removal_of_the_nuclear_localization_signal_which_can_cause_cellular_mislocalization_(French_2003,_PMID:12966089)._This_variant_is_not_listed_in_population_databases._It_has_been_reported_in_an_unaffected_control_individual_and_in_individuals_with_breast_cancer,_ovarian_cancer,_and_uterine_cancer_in_multiple_studies_(Loveday_2012,_PMID:22538716:_Golmard_2013,_PMID:2413955:_Janatova_2015,_PMID:26057125:_Kraus_2017,_PMID:27616075)._Bayesian_analysis_integrating_all_of_this_data_(Tavtigian_et_al,_2018,_PMID:29300386)_gives_about_98%_probability_of_pathogenicity_based_largely_on_splice_prediction_and_functional_studies,_which_are_consistent_with_a_classification_of_likely_pathogenic._This_variant_is_predicted_to_alter_RAD51C_function_and_modify_risk_for_cancer._This_analysis_was_performed_in_conjunction_with_the_family_studies_project_as_part_of_the_University_of_Washington_Find_My_Variant_Study.|	TCGA_UCEC_287
NM_000535.6:c.137G>T	PMS2	missense_variant	4&5&5	3&2&1	rs121434629	Lynch syndrome&Hereditary cancer-predisposing syndrome&not provided	9245	24284	Pituitary_carcinoma|Hereditary_nonpolyposis_colon_cancer|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Lynch_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_4|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0011763,MedGen:C0346300,Orphanet:ORPHA300385|MedGen:C0009405,Orphanet:ORPHA443090|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C1838333,OMIM:614337|MedGen:CN169374|MedGen:CN517202	-	NC_000007.13:g.6045549C>A	reviewed_by_expert_panel	Likely_pathogenic	-	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:600259.0012|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:3554|Illumina_Clinical_Services_Laboratory,Illumina:616257|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.137G>T_2|UniProtKB_(protein):P54278#VAR_066838	-	PMS2:5395	SO:0001583|missense_variant,SO:0001619|non-coding_transcript_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	121434629	-	OMIM|CSER__CC_NCGL,_University_of_Washington|OMIM|Illumina_Clinical_Services_Laboratory,Illumina|Counsyl|Equipe_Genetique_des_Anomalies_du_Developpement,_Université_de_Bourgogne|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Mendelics|International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT)|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Mendelics|Integrated_Genetics/Laboratory_Corporation_of_America|Ambry_Genetics|Vantari_Genetics|Color|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Invitae|Clinical_Genomics_Lab,St._Jude_Children's_Research_Hospital|Fulgent_Genetics,Fulgent_Genetics	Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2013-08-01|2014-06-01|2013-08-01|2016-09-27|2015-05-14|2017-04-19|2018-04-10|2019-05-28|2019-06-21|2015-11-20|2018-03-23|2014-12-11|2018-07-02|2017-11-21|2019-02-12|2016-01-26|2015-07-25|2018-09-28|2015-02-27|2015-12-04|2018-07-16|2018-12-30|2016-03-18|2018-10-31	2016-12-27|2014-08-28|2016-12-27|2019-02-01|2017-06-22|2018-02-06|2018-06-14|2019-10-22|2019-06-21|2016-03-03|2019-03-21|2017-04-19|2018-08-20|2019-04-24|2020-02-26|2016-03-29|2017-10-26|2019-01-29|2018-09-19|2017-08-01|2019-08-05|2019-03-28|2018-08-09|2018-11-14	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|reviewed_by_expert_panel|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|unknown|germline|unknown|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown	SCV000030047|SCV000190470|SCV000087493|SCV000469744|SCV000677739|SCV000803859|SCV000840051|SCV001137331|SCV000108292|SCV000266116|SCV000271259|SCV000592923|SCV000838198|SCV000918033|SCV000184825|SCV000267076|SCV000686122|SCV000149566|SCV000227140|SCV000601815|SCV000604885|SCV000253845|SCV000853190|SCV000894431	Turcot_syndrome|Turcot_syndrome|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Hereditary_nonpolyposis_colorectal_cancer_type_4|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|not_specified|Hereditary_nonpolyposis_colon_cancer|Pituitary_carcinoma|Turcot_syndrome/Hereditary_nonpolyposis_colorectal_cancer_type_4	|||Across_a_selection_of_the_available_literature,_the_PMS2_c.137G>T_(p.Ser46Ile)_missense_variant_has_been_identified_in_at_least_18_heterozygous_or_compound_heterozygous_cases_with_various_cancers_and_three_as-yet_unaffected_heterozygous_family_members_(Agostini_et_al._2005:_Auclair_et_al._2007:_Senter_et_al._2008:_Pastrello_et_al._2011:_Herkert_et_al._2011:_Tomsic_et_al._2013:_Borras_et_al._2013)._The_p.Ser46Ile_variant_was_absent_from_188_control_individuals_and_436_control_chromosomes_but_is_reported_at_a_frequency_of_0.00022_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._The_variant_occurs_at_a_strongly_conserved_residue_in_an_important_functional_domain._Borras_et_al._(2013)_demonstrated_through_in_vitro_expressions_studies_that_the_p.Ser46Ile_variant_had_significantly_reduced_mismatch_repair_activity,_approximately_13%_that_of_wild_type,_while_Drost_et_al._(2013)_showed_that_the_p.Ser46Ile_variant_had_a_mismatch_repair_efficiency_similar_to_that_of_a_known_pathogenic_variant._Based_on_the_evidence,_the_p._Ser46Ile_variant_is_classified_as_likely_pathogenic_for_Lynch_syndrome._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.|||This_c.137G>T_(p.S46I)_variant_in_PMS2_has_been_reported_in_individuals_with_mismatch_repair_deficiency_syndrome,_colon,_endometrial,_colorectal_and_bladder_cancer_(PMID:_21376568,_16144131,_21204794,_22577899,_16619239,_23709753)._In_addition,_functional_studies_have_shown_that_the_c.137G>T_(p.S46I)_variant_significantly_impairs_mismatch_repair_activity_(PMID:_23709753,_24027009)._Therefore,_the_c.137G>T_(p.S46I)_in_the_PMS2_gene_is_classified_as_pathogenic.||>2_MSI_tumours:_deficient_protein_function_inferred_from_2_independent_assays||The_p.Ser46Ile_variant_in_PMS2_has_been_described_as_a_founder_variant_for_lynch_syndrome_in_Caucasians_(Ponti_2015,_Tomsic_2013)._It_has_been_reported_in_the_h_eterozygous_state_in_>15_individuals_with_Lynch_syndrome-associated_cancers,_whe_re_the_tumors_showed_microsatellite_instability_and_loss_of_PMS2_expression_in_s_ome_individuals_(Borras_2013,_Clendenning_2006,_Cock-Rada_2017,_Haraldsdottir_20_13,_Le_2017,_Nakagawa_2004,_Pritchard_2016,_Senter_2008,_Tomsic_2013,_ClinVar:_V_ariation_ID_9245)._This_variant_has_also_been_reported_in_the_biallelic_state_(h_omozygous_or_compound_heterozygous_with_a_second_pathogenic_variant)_in_at_least_9_individuals_with_constitutional_mismatch_repair_deficiency_syndrome_(CMMRD)_a_nd_segregated_with_disease_in_at_least_3_affected_relatives_from_at_least_2_fami_lies_(Auclair_2007,_Borras_2013,_Giunti_2009,_Herkert_2011)._Normal_and_tumor_ti_ssue_from_some_individuals_with_CMMRD_showed_loss_of_expression_of_PMS2_(Agostin_i_2005,_Auclair_2007,_Bodo_2015,_Giunti_2009,_Herkert_2011,_Jackson_2008,_Lavoin_e_2015,_Pastrello_2011,_Stark_2014)._Additionally,_some_relatives_who_were_heter_ozygous_carriers_of_this_variant_were_clinically_unaffected,_suggesting_reduced_penetrance._In_vitro_functional_studies_provide_some_evidence_that_the_p.Ser46Il_e_variant_may_impact_protein_function_(Borras_2013,_Drost_2013,_Nakagawa_2004)._This_variant_has_been_identified_in_35/122744_European_chromosomes_by_the_Genome_Aggregation_Database_(gnomAD,_http://gnomad.broadinstitute.org:_dbSNP_rs1214346_29)._Although_this_variant_has_been_seen_in_the_general_population,_its_frequenc_y_is_low_enough_to_be_consistent_with_the_frequency_and_penetrance_of_PMS2-relat_ed_Lynch_syndrome._Computational_prediction_tools_and_conservation_analysis_sugg_est_that_the_p.Ser46Ile_variant_may_impact_the_protein._In_summary,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_Lynch_syndrome_in_an_autosoma_l_dominant_manner_and_for_CMMRD_in_an_autosomal_recessive_manner_based_upon_pres_ence_in_multiple_affected_individuals,_segregation_studies,_and_functional_evide_nce._ACMG/AMP_Criteria_applied_(Richards_2015):_PM3_Very_strong:_PS3:_PS4:_PP1:_PP3.|||Variant_summary:_The_PMS2_c.137G>T_(p.Ser46Ile)_variant_involves_the_alteration_of_a_conserved_nucleotide_that_results_in_a_missense_change_within_the_nucleotide_binding_pocket_of_the_ATPase_domain_(Borras_2013)._4/4_in_silico_tools_predict_a_damaging_outcome_for_this_variant_(SNPsandGO_not_captured_due_to_low_reliability_index)._Functional_studies_have_shown_the_variant_to_cause_deficient_MMR_activity_(Borras_2013,_Drost_2013,_van_der_Klift_2016)._This_variant_was_found_in_47/271742_control_chromosomes_(in_gnomAD_and_publication_controls),_however_the_technology_utilized_for_the_gnomAD_dataset_does_not_rule_out_pseudogene_interference_and_thus_this_data_cannot_be_relied_upon._This_variant_has_been_reported_in_several_patients/families_with_Lynch_syndrome-associated_cancers_(in_many_cases_isolated_loss_of_PMS2_was_detected_in_the_tumors)_as_well_as_in_patients_with_constitutional_MMR_deficiency_(CMMR-D)_syndrome_who_also_have_a_second_pathogenic_PMS2_mutation_(in_many_of_these_cases_PMS2_loss_in_normal_tissues_was_documented)_(Clendenning_2006,_Senter_2008,_Herkert_2011,_Tomsic_2013,_Borras_2013,_van_der_Klift_2016)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_pathogenic._Taken_together,_this_variant_is_classified_as_pathogenic.|Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s):Other_strong_data_supporting_pathogenic_classification|||This_pathogenic_variant_is_denoted_PMS2_c.137G>T_at_the_cDNA_level,_p.Ser46Ile_(S46I)_at_the_protein_level,_and_results_in_the_change_of_a_Serine_to_an_Isoleucine_(AGT>ATT)._PMS2_Ser46Ile_was_observed_at_an_allele_frequency_of_0.03%_(11/34312)_in_individuals_of_Latino_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_Motif_I_of_the_ATPase_domain_(Guarne_2001)._In-silico_analyses,_including_protein_predictors_and_evolutionary_conservation,_support_a_deleterious_effect._PMS2_Ser46Ile_has_been_published_in_the_literature_as_a_Caucasian_founder_pathogenic_variant_(Senter_2008,_Tomsic_2013,_Ponti_2015)._It_has_been_reported_in_many_individuals_with_Lynch_syndrome-associated_tumors_and_in_many_individuals_with_autosomal_recessive_constitutional_mismatch_repair_deficiency_syndrome_(CMMR-D)_in_the_homozygous_state_or_in_the_compound_heterozygous_state_with_a_second_PMS2_pathogenic_variant_on_the_opposite_chromosome._Tumor_testing_in_many_of_these_individuals_showed_microsatellite_instability_(MSI-H)_and/or_loss_of_PMS2_protein_expression_(Nakagawa_2004,_Agostini_2005,_Clendenning_2006,_Auclair_2007,_Jackson_2008,_Senter_2008,_Van_der_Klift_2010,_Hekert_2011,_Leenen_2011,_Lavoine_2015,_ten_Broeke_2015,_Heath_2016,_Nowak_2016,_van_der_Klift_2016,_Rengifo-Cam_2017)._While_some_functional_studies_have_been_inconclusive,_several_independent_in_vitro_cell-free_complementation_assays_showed_deficient_mismatch_repair_activity_as_well_as_reduced_PMS2_expression_(Nakagawa_2004,_Borras_2013,_Drost_2013)._Based_on_currently_available_evidence,_we_consider_PMS2_Ser46Ile_to_be_a_pathogenic_variant.|||The_PMS2_c.137G>T:p.Ser46Ile_variant_has_been_published_in_the_literature_in_individuals_and_families_with_Lynch_syndrome-associated_cancers_and_constitutional_mismatch_repair-deficiency_(Auclair_2007,_Borras_2013,_Jackson_2008,_Senter_2008,_Tosmic_2013)._This_variant_is_reported_as_pathogenic_by_multiple_laboratories_in_ClinVar_(Variation_ID:_9245)_and_is_found_in_the_Latino_population_with_an_overall_allele_frequency_of_0.03%_(11/34312_alleles)_in_the_Genome_Aggregation_Database._Several_individuals_with_constitutional_mismatch_repair-deficiency_carried_this_variant_in_trans_to_a_second_pathogenic_PMS2_variant_(Auclair_2007,_Jackson_2008,_Senter_2008),_including_another_variant_at_the_same_codon,_p.Ser46Asn,_observed_in_two_affected_individuals_(Jackson_2008,_Senter_2008)._The_serine_at_codon_46_is_highly_conserved_and_both_the_p.Ser46Ile_and_p.Ser46Asn_variants_exhibit_less_than_10%_of_wild-type_activity_in_mismatch_repair_in_vitro_assays_(Borras_2013,_Drost_2013)._Based_on_available_information,_this_variant_is_considered_to_be_pathogenic._References:_Auclair_J_et_al._Novel_biallelic_mutations_in_MSH6_and_PMS2_genes:_gene_conversion_as_a_likely_cause_of_PMS2_gene_inactivation._Hum_Mutat._2007_Nov:28(11):1084-90._Borras_E_et_al._Refining_the_role_of_PMS2_in_Lynch_syndrome:_germline_mutational_analysis_improved_by_comprehensive_assessment_of_variants._J_Med_Genet._2013_Aug:50(8):552-63._Drost_M_et_al._Inactivation_of_DNA_mismatch_repair_by_variants_of_uncertain_significance_in_the_PMS2_gene._Hum_Mutat._2013_Nov:34(11):1477-80._Jackson_CC_et_al._Cafe-au-lait_macules_and_pediatric_malignancy_caused_by_biallelic_mutations_in_the_DNA_mismatch_repair_(MMR)_gene_PMS2._Pediatr_Blood_Cancer._2008_Jun:50(6):1268-70._Senter_L_et_al._The_clinical_phenotype_of_Lynch_syndrome_due_to_germ-line_PMS2_mutations._Gastroenterology._2008_Aug:135(2):419-28._Tomsic_J_et_al._Recurrent_and_founder_mutations_in_the_PMS2_gene._Clin_Genet._2013_Mar:83(3):238-43.|This_sequence_change_replaces_serine_with_isoleucine_at_codon_46_of_the_PMS2_protein_(p.Ser46Ile)._The_serine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_serine_and_isoleucine._This_variant_is_present_in_population_databases_(rs121434629,_ExAC_0.02%)._This_variant_has_been_reported_in_trans_with_pathogenic_PMS2_variants_in_multiple_families_with_constitutional_mismatch_repair_deficiency_syndrome_(CMMR-D)_(PMID:_21376568,_16144131,_21204794)._In_separate_analyses,_this_c.137G>T_missense_variant_was_identified_in_more_than_10_probands_with_colon_and/or_endometrial_cancer_(PMID:_22577899,_16619239),_and_has_been_reported_to_segregate_with_colorectal_and_bladder_cancer_in_a_single_family_with_suspected_Lynch_syndrome_(PMID:_23709753)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_9245)._Experimental_studies_have_shown_that_this_missense_change_significantly_impairs_the_mismatch_repair_activity_of_PMS2_(PMID:_23709753,_24027009)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|This_is_a_missense_variant_in_which_a_G_is_replaced_by_a_T_at_coding_position_137_and_is_predicted_to_change_a_Serine_to_an_Isoleucine_at_codon_46.|	TCGA_UCEC_469
